Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration

• Published in: Cancer chemotherapy and pharmacology Vol. 42; no. 6; pp. 433 - 440
• Main Authors: Marzolini, Catia, Shen, Fei, Bauer, Jean, Buclin, Thierry, Biollaz, J r me, Decosterd, Laurent A., Lejeune, Ferdy, Gander, Marc, Leyvraz, Serge
• Format: Journal Article
• Language: English
• Published: Berlin Springer 1998
• Subjects: Administration, Oral; Adult; Aged; Antineoplastic agents; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Blood-Brain Barrier; Brain Neoplasms - drug therapy; Chemotherapy; Dacarbazine - administration & dosage; Dacarbazine - adverse effects; Dacarbazine - analogs & derivatives; Dacarbazine - cerebrospinal fluid; Female; Glioma - drug therapy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Male; Medical sciences; Melanoma - drug therapy; Middle Aged; Nitrosourea Compounds - administration & dosage; Organophosphorus Compounds - administration & dosage; Pharmacology. Drug treatments; Antineoplastic agent; Human; Urine; Biological fluid; Plasma; Intrahepatic administration; Nervous system diseases; Drug combination; Intravenous administration; Toxicity; Oral administration; Tolerance; Malignant tumor; Bioavailability; Fotemustine; Blood; Malignant glioma; Chemotherapy; Treatment; Central nervous system disease; Malignant melanoma; Temozolomide; Pharmacokinetics

Depletion of the DNA repair enzyme O6-alkylguanine-DNA alkyltransferase (AT) has been shown to increase tumor sensitivity to chloroethylnitrosoureas. Temozolomide (TMZ), an analogue of dacarbazine, can deplete AT, suggesting that it may be used to sensitize tumors to chloroethylnitrosoureas. However...